CytomX Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
CytomX Therapeutics, Inc. (CTMX) reported Basic Shares Outstanding (Weighted Average) of 218.94 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- CytomX Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 218.94M shares, a 69.62% increase year-over-year.
- CytomX Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 177.27M shares, a 103.48% increase year-over-year.
- CytomX Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 169.69M shares, a 97.90% increase year-over-year.
- CytomX Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 165.00M shares, a 93.91% increase year-over-year.
- CytomX Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 137.94M shares, a 63.36% increase from fiscal 2024.
- CytomX Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 84.44M shares, a 14.40% increase from fiscal 2023.
- CytomX Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 73.81M shares, a 12.27% increase from fiscal 2022.
- CytomX Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 65.74M shares, a 2.48% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 218.94M shares 10-Q · filed 2026-08-06 | 198.22M shares 10-Q · filed 2026-08-06 | 188.63M shares derived: average of 3 quarters · filed 2026-08-06 | 182.73M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 177.27M shares 10-Q · filed 2026-05-07 | 173.48M shares derived: average of 2 quarters · filed 2026-05-07 | 170.65M shares derived: average of 3 quarters · filed 2026-05-07 | 160.26M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 169.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 167.35M shares derived: average of 2 quarters · filed 2026-03-16 | 154.59M shares derived: average of 3 quarters · filed 2026-08-06 | 137.94M shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 165.00M shares 10-Q · filed 2025-11-06 | 147.04M shares derived: average of 2 quarters · filed 2026-08-06 | 127.35M shares 10-Q · filed 2025-11-06 | 116.74M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 129.08M shares 10-Q · filed 2026-08-06 | 108.21M shares 10-Q · filed 2026-08-06 | 100.65M shares derived: average of 3 quarters · filed 2026-08-06 | 96.76M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 87.12M shares 10-Q · filed 2026-05-07 | 86.43M shares derived: average of 2 quarters · filed 2026-05-07 | 85.99M shares derived: average of 3 quarters · filed 2026-05-07 | 85.71M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 85.74M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 85.42M shares derived: average of 2 quarters · filed 2026-03-16 | 85.24M shares derived: average of 3 quarters · filed 2026-03-16 | 84.44M shares 10-K · filed 2026-03-16 |
| 2024-09-30 | 85.09M shares 10-Q · filed 2025-11-06 | 84.99M shares derived: average of 2 quarters · filed 2025-11-06 | 84.01M shares 10-Q · filed 2025-11-06 | 83.39M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 84.88M shares 10-Q · filed 2025-08-07 | 83.46M shares 10-Q · filed 2025-08-07 | 82.82M shares derived: average of 3 quarters · filed 2025-08-07 | 82.30M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 82.03M shares 10-Q · filed 2025-05-12 | 81.79M shares derived: average of 2 quarters · filed 2025-05-12 | 81.44M shares derived: average of 3 quarters · filed 2025-05-12 | 77.71M shares derived: average of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | 81.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 81.14M shares derived: average of 2 quarters · filed 2025-03-06 | 76.27M shares derived: average of 3 quarters · filed 2025-03-06 | 73.81M shares 10-K · filed 2025-03-06 |
| 2023-09-30 | 80.73M shares 10-Q · filed 2024-11-07 | 73.63M shares derived: average of 2 quarters · filed 2024-11-07 | 71.23M shares 10-Q · filed 2024-11-07 | 69.91M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | 66.54M shares 10-Q · filed 2024-08-08 | 66.39M shares 10-Q · filed 2024-08-08 | 66.30M shares derived: average of 3 quarters · filed 2024-08-08 | 66.20M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 66.25M shares 10-Q · filed 2024-05-08 | 66.18M shares derived: average of 2 quarters · filed 2024-05-08 | 66.09M shares derived: average of 3 quarters · filed 2024-05-08 | 65.95M shares derived: average of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | 66.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 66.01M shares derived: average of 2 quarters · filed 2024-03-11 | 65.85M shares derived: average of 3 quarters · filed 2024-03-11 | 65.74M shares 10-K · filed 2024-03-11 |
| 2022-09-30 | 65.91M shares 10-Q · filed 2023-11-07 | 65.73M shares derived: average of 2 quarters · filed 2023-11-07 | 65.62M shares 10-Q · filed 2023-11-07 | 65.54M shares derived: average of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | 65.54M shares 10-Q · filed 2023-08-08 | 65.47M shares 10-Q · filed 2023-08-08 | 65.41M shares derived: average of 3 quarters · filed 2023-08-08 | 65.36M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 65.39M shares 10-Q · filed 2023-05-09 | 65.34M shares derived: average of 2 quarters · filed 2023-05-09 | 65.30M shares derived: average of 3 quarters · filed 2023-05-09 | 65.24M shares derived: average of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | 65.30M shares 10-K/A · filed 2023-03-27 | 65.25M shares derived: average of 2 quarters · filed 2023-03-27 | 65.19M shares derived: average of 3 quarters · filed 2023-03-27 | 64.15M shares 10-K/A · filed 2023-03-27 |
| 2021-09-30 | 65.21M shares 10-K/A · filed 2023-03-27 | 65.13M shares derived: average of 2 quarters · filed 2023-03-27 | 63.76M shares 10-K/A · filed 2023-03-27 | 59.46M shares derived: average of 4 quarters · filed 2023-03-27 |
| 2021-06-30 | 65.06M shares 10-K/A · filed 2023-03-27 | 63.02M shares 10-K/A · filed 2023-03-27 | 57.54M shares derived: average of 3 quarters · filed 2023-03-27 | 54.70M shares derived: average of 4 quarters · filed 2023-03-27 |
| 2021-03-31 | 60.97M shares 10-K/A · filed 2023-03-27 | 53.78M shares derived: average of 2 quarters · filed 2023-03-27 | 51.25M shares derived: average of 3 quarters · filed 2023-03-27 | 49.96M shares derived: average of 4 quarters · filed 2023-03-27 |
| 2020-12-31 | 46.60M shares 10-K/A · filed 2023-03-27 | 46.40M shares derived: average of 2 quarters · filed 2023-03-27 | 46.28M shares derived: average of 3 quarters · filed 2023-03-27 | 46.15M shares 10-K/A · filed 2023-03-27 |
| 2020-09-30 | 46.20M shares 10-K/A · filed 2023-03-27 | 46.13M shares derived: average of 2 quarters · filed 2023-03-27 | 45.99M shares 10-K/A · filed 2023-03-27 | |
| 2020-06-30 | 46.06M shares 10-K/A · filed 2023-03-27 | 45.89M shares 10-K/A · filed 2023-03-27 | ||
| 2020-03-31 | 45.72M shares 10-K/A · filed 2023-03-27 | |||
| 2019-12-31 | 45.34M shares 10-K/A · filed 2023-03-27 | |||
| 2019-03-31 | 45.12M shares 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |